Immutep Limited Corporate Presentation 2024 - LAG-3 Immunotherapy

Immutep is a LAG-3 pure-play biopharmaceutical company developing eftilagimod alfa (efti) as a first-in-class immunotherapy for cancer and autoimmune diseases. The company has four clinical-stage assets with a Phase III program partnered with MSD in first-line non-small cell lung cancer, supported by ~$182 million in cash providing runway through 2026.